Omeprazole

Generic Name
Omeprazole
Brand Names
Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
Drug Type
Small Molecule
Chemical Formula
C17H19N3O3S
CAS Number
73590-58-6
Unique Ingredient Identifier
KG60484QX9
Background

Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...

Indication

Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:

• Treatment of active duodenal ulcer in adults

• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults

• Treatment of active benign gastric ulcer in adults
...

Associated Conditions
Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
Associated Therapies
-
Clinical Trials
Related News

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: Clopidogrel
Drug: Omeprazole
First Posted Date
2010-05-24
Last Posted Date
2011-12-15
Lead Sponsor
Sanofi
Target Recruit Count
72
Registration Number
NCT01129414
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: clopidogrel
Drug: omeprazole
First Posted Date
2010-05-24
Last Posted Date
2011-12-15
Lead Sponsor
Sanofi
Target Recruit Count
72
Registration Number
NCT01129388
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: clopidogrel
Drug: placebo
Drug: omeprazole
First Posted Date
2010-05-24
Last Posted Date
2011-12-15
Lead Sponsor
Sanofi
Target Recruit Count
72
Registration Number
NCT01129375
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Gastric pH and Anthocyanin Absorption

Not Applicable
Completed
Conditions
Anthocyanin Metabolism
Interventions
Drug: placebo
Drug: omeprazole
First Posted Date
2010-05-13
Last Posted Date
2013-08-23
Lead Sponsor
USDA Beltsville Human Nutrition Research Center
Target Recruit Count
13
Registration Number
NCT01122160
Locations
🇺🇸

USDA's Beltsville Human Nutrition Research Center, Beltsville, Maryland, United States

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

First Posted Date
2010-03-26
Last Posted Date
2016-03-17
Lead Sponsor
Mayo Clinic
Target Recruit Count
30
Registration Number
NCT01093755
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Omeprazole
First Posted Date
2010-01-11
Last Posted Date
2010-01-20
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
62
Registration Number
NCT01045434
Locations
🇮🇳

Wellquest Clinical Research, Mumbai, Maharashtra, India

Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsules Under Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Omeprazole
First Posted Date
2010-01-11
Last Posted Date
2010-01-20
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
38
Registration Number
NCT01045642
Locations
🇮🇳

Vimta Labs Limited, Hyderabad, Andhra Pradesh, India

Clopidogrel Proton-Pump Inhibitors Study

Phase 4
Withdrawn
Conditions
Coronary Artery Disease
Interventions
Drug: Omeprazole
Drug: Pantoprazole
First Posted Date
2009-11-19
Last Posted Date
2016-10-21
Lead Sponsor
Sheba Medical Center
Registration Number
NCT01016717
Locations
🇮🇱

Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

First Posted Date
2009-10-23
Last Posted Date
2017-03-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
18
Registration Number
NCT01000818

Evaluation of Omeprazole Effect on Glaucoma

Phase 1
Conditions
Glaucoma
Interventions
Drug: Placebo
Drug: Omeprazole
First Posted Date
2009-10-22
Last Posted Date
2010-05-04
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Registration Number
NCT01000220
Locations
🇮🇷

Ophthalmic Research Center, Tehran, Iran, Islamic Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy